The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Thyrotropin Suppression and Disease Progression in Patients with Differentiated Thyroid Cancer: Results from the National Thyroid Cancer Treatment Cooperative Registry
Abstract
The ideal therapy for differentiated thyroid cancer is uncertain. Although thyroid hormone treatment is pivotal, the degree of thyrotropin (TSH) suppression that is required to prevent recurrences has not been studied in detail. We have examined the relation of TSH suppression to baseline disease characteristics and to the likelihood of disease progression in a cohort of thyroid cancer patients who have been followed in a multicenter thyroid cancer registry that was established in 1986. The present study describes 617 patients with papillary and 66 patients with follicular thyroid cancer followed annually for a median of 4.5 years (range 1-8.6 years). Cancer staging was assessed using a staging scheme developed and validated by the registry. Cancer status was defined as no residual disease; progressive disease at any follow-up time; or death from thyroid cancer. A mean TSH score was calculated for each patient by averaging all available TSH determinations, where 1 = undetectable TSH; 2 = subnormal TSH; 3 = normal TSH; and 4 = elevated TSH. Patients were also grouped by their TSH scores: group 1: mean TSH score 1.0-1.99; group 2: mean TSH score 2.0-2.99; group 3: mean TSH score 3.0-4.0. The degree of TSH suppression did not differ between papillary and follicular thyroid cancer patients. However, TSH suppression was greater in papillary cancer patients who were initially classified as being at higher risk for recurrence. This was not the case for follicular cancer patients, where TSH suppression was similar for all patients. For all stages of papillary cancer, a Cox proportional hazards model showed that disease stage, patient age, and radioiodine therapy all predicted disease progression, but TSH score category did not. However, TSH score category was an independent predictor of disease progression in high risk patients (p = 0.03), but was no longer significant when radioiodine therapy was included in the model (p = 0.09). There were too few patients with follicular cancer for multivariate analysis. These data suggest that physicians use greater degrees of TSH suppression in higher risk papillary cancer patients. Our data do not support the concept that greater degrees of TSH suppression are required to prevent disease progression in low-risk patients, but this possibility remains in high-risk patients. Additional studies with more patients and longer follow-up may provide the answer to this important question.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer
Mazzaferri, E. L., & Jhiang, S. M. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90321-2 · Cited by 2,635
Low Serum Thyrotropin Concentrations as a Risk Factor for Atrial Fibrillation in Older Persons
Sawin, C. T., Geller, A., Wolf, P. A., Belanger, A. J., Baker, E., Bacharach, P., Wilson, P., Benjamin, E. J., & D'Agostino, R. B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411103311901 · Cited by 1,259
National Thyroid Cancer Treatment Cooperative Study Registr Group, Sherman, S. I., Brierley, J. D., Sperling, M., Ain, K. B., Bigos, S. T., Cooper, D. S., Haugen, B. R., Ho, M., Klein, I., et al. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980901)83:5<1012::aid-cncr28>3.0.co;2-9 · Cited by 402
Self-citationEffects on bone mass of long term treatment with thyroid hormones: a meta-analysis
Uzzan, B., Campos, J., Cucherat, M., Nony, P., Boissel, J. P., & Perret, G. Y. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.12.8954028 · Cited by 398
Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer
Pujol, P. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.12.4318 · Cited by 320
Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine
Biondi, B. (1993) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.77.2.334 · Cited by 133
Human Thyroid Cancer: Membrane Thyrotropin Binding and Adenylate Cyclase Activity
Carayon, P., Thomas-Morvan, C., Castanas, E., & Tubiana, M. (1980) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-51-4-915 · Cited by 95
Medical Therapy for Differentiated Thyroid Carcinoma*
Dulgeroff, A. J., & Hershman, J. M. (1994) · Endocrine Reviews · doi:10.1210/edrv-15-4-500 · Cited by 90
Endocrine Dependency of Papillary Carcinomas of the Thyroid
Crile, G. (1966) · JAMA · doi:10.1001/jama.1966.03100090055013 · Cited by 84
Spencer, C. A., LAI-ROSENFELD, A. O., Guttler, R., LoPresti, J. S., Marcus, A. O., Nimalasuriya, A., EOGEN, A., DOSS, R. C., Green, B. J., & Nicoloff, J. T. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-349 · Cited by 56
Cited by
Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., Pacini, F., Randolph, G. W., Sawka, A. M., Schlumberger, M., et al. (2016) · Thyroid® · doi:10.1089/thy.2015.0020 · Cited by 16,535
Self-citationCooper, D. S., Doherty, G. M., Haugen, B. R., Kloos, R. T., Lee, S. L., Mandel, S. J., Mazzaferri, E. L., McIver, B., Pacini, F., Schlumberger, M., et al. (2009) · Thyroid · doi:10.1089/thy.2009.0110 · Cited by 6,707
Self-citationCooper, D. S., Doherty, G. M., Haugen, B. R., Kloos, R. T., Lee, S. L., Mandel, S. J., Mazzaferri, E. L., McIver, B., Sherman, S. I., & Tuttle, R. M. (2006) · Thyroid · doi:10.1089/thy.2006.16.109 · Cited by 2,016
Self-citationClinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)
Thakker, R. V., Newey, P. J., Walls, G. V., Bilezikian, J., Dralle, H., Ebeling, P. R., Melmed, S., Sakurai, A., Tonelli, F., & Brandi, M. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1230 · Cited by 1,477
Francis, G. L., Waguespack, S. G., Bauer, A. J., Angelos, P., Benvenga, S., Cerutti, J. M., Dinauer, C. A., Hamilton, J., Hay, I. D., Luster, M., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0460 · Cited by 1,238
Metadata
- Authors
- COOPER, D. S., SPECKER, B., HO, M., SPERLING, M., LADENSON, P. W., ROSS, D. S., AIN, K. B., BIGOS, S. T., BRIERLEY, J. D., HAUGEN, B. R., KLEIN, I., ROBBINS, J., SHERMAN, S. I., TAYLOR, T., & MAXON, H. R.
- Venue
- Thyroid
- Publisher
- SAGE Publications
- Published
- 1998-09
- Volume
- 8
- Issue
- 9
- Pages
- 737-744
- ISSN
- 1050-7256 (ISSN-L)
- 1557-9077
- OpenAlex
- W2046987218
- Cited by
- 353
- References
- 10
- FWCI
- 5.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Thyrotropin Suppression and Disease Progression in Patients with Differentiated Thyroid Cancer: Results from the National Thyroid Cancer Treatment Cooperative Registry. https://app.cochat.ai/papers/10.1089/thy.1998.8.737
- The paper
- COOPER, D. S., SPECKER, B., HO, M., SPERLING, M., LADENSON, P. W., ROSS, D. S., AIN, K. B., BIGOS, S. T., BRIERLEY, J. D., HAUGEN, B. R., KLEIN, I., ROBBINS, J., SHERMAN, S. I., TAYLOR, T., & MAXON, H. R. (1998). Thyrotropin Suppression and Disease Progression in Patients with Differentiated Thyroid Cancer: Results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid. https://doi.org/10.1089/thy.1998.8.737
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.